Equities research analysts expect Imperva Inc (NASDAQ:IMPV) to announce earnings of $0.14 per share for the current quarter, according to Zacks. Seven analysts have provided estimates for Imperva’s earnings. The lowest EPS estimate is $0.11 and the highest is $0.24. Imperva reported earnings of $0.40 per share during the same quarter last year, which indicates a negative year-over-year growth rate of 65%. The business is expected to issue its next quarterly earnings results on Thursday, February 14th.
On average, analysts expect that Imperva will report full-year earnings of $0.33 per share for the current year, with EPS estimates ranging from $0.22 to $0.49. For the next year, analysts expect that the company will post earnings of $0.93 per share, with EPS estimates ranging from $0.79 to $1.06. Zacks’ EPS calculations are a mean average based on a survey of sell-side research analysts that follow Imperva.
Imperva (NASDAQ:IMPV) last posted its quarterly earnings results on Wednesday, October 31st. The software maker reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.18 by $0.25. The business had revenue of $91.63 million for the quarter, compared to analysts’ expectations of $89.24 million. Imperva had a negative return on equity of 5.62% and a negative net margin of 8.00%.
A number of brokerages have issued reports on IMPV. BidaskClub cut Imperva from a “strong-buy” rating to a “buy” rating in a report on Wednesday, November 28th. Zacks Investment Research upgraded Imperva from a “hold” rating to a “buy” rating and set a $62.00 target price on the stock in a report on Friday, October 12th. Macquarie cut Imperva from an “outperform” rating to a “neutral” rating and set a $55.00 target price on the stock. in a report on Thursday, October 11th. Evercore ISI restated a “hold” rating and set a $55.75 target price on shares of Imperva in a report on Thursday, October 11th. Finally, DA Davidson set a $56.00 target price on Imperva and gave the stock a “hold” rating in a report on Thursday, October 11th. Eleven analysts have rated the stock with a hold rating and six have assigned a buy rating to the company. The stock presently has an average rating of “Hold” and an average price target of $56.37.
Shares of IMPV opened at $55.52 on Friday. Imperva has a 1 year low of $37.17 and a 1 year high of $57.65. The stock has a market cap of $1.95 billion, a price-to-earnings ratio of -198.29 and a beta of 1.29.
A number of institutional investors and hedge funds have recently modified their holdings of the business. Public Employees Retirement Association of Colorado raised its position in shares of Imperva by 142.6% during the third quarter. Public Employees Retirement Association of Colorado now owns 2,608 shares of the software maker’s stock worth $121,000 after purchasing an additional 1,533 shares during the period. Royal Bank of Canada raised its position in shares of Imperva by 99.4% during the first quarter. Royal Bank of Canada now owns 2,794 shares of the software maker’s stock worth $122,000 after purchasing an additional 1,393 shares during the period. Aperio Group LLC acquired a new stake in shares of Imperva during the second quarter worth about $203,000. Oppenheimer & Co. Inc. acquired a new stake in shares of Imperva during the second quarter worth about $222,000. Finally, Global Endowment Management LP acquired a new stake in shares of Imperva during the third quarter worth about $390,000. Hedge funds and other institutional investors own 93.43% of the company’s stock.
Imperva Company Profile
Imperva, Inc engages in the development, market, sale, and support of cyber security solutions that protect business critical data and applications in the cloud or on premises worldwide. The company's SecureSphere product line provides database, file, and Web application security in various data centers, including on-premises data centers, as well as in private, public, and hybrid cloud computing environments.
Featured Article: How can investors find ex-dividend dates?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva and related companies with MarketBeat.com's FREE daily email newsletter.